Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Pharvaris N.V. Q4 2023 EPS €(0.74) Vs €(1.16) YoY; Cash And Cash Equivalents Were ~€391 Million As Of December 31, 2023

Author: Benzinga Newsdesk | April 10, 2024 04:14pm

Fourth Quarter and Full Year 2023 Financial Results

  • Liquidity Position. Cash and cash equivalents were approximately €391 million as of December 31, 2023, compared to approximately €162 million for December 31, 2022.
  • Research and Development (R&D) Expenses. R&D expenses were €18.6 million for the fourth quarter and €65.6 million for the full year of 2023, compared to €15.7 million for the fourth quarter and €57.4 million for the full year of 2022.
  • General and Administrative (G&A) Expenses. G&A expenses were €8.6 million for the fourth quarter and €31.3 million for the full year of 2023, compared to €7.8 million for the fourth quarter and €29.3 million for the full year of 2022.
    • Loss for the year. Loss for the fourth quarter of 2023 was €32.7 million, resulting in basic and diluted loss per share of €0.74. For the full year of 2023, loss was €101 million, resulting in basic and diluted loss per share of €2.63 per share. This compares to €39.2 million, or basic and diluted loss per share of €1.16, for the fourth quarter of 2022 and €76.3 million, or basic and diluted loss per share of €2.27, for the full year of 2022.

Posted In: PHVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist